Vertex Pharmaceuticals and AI-related tech firms see market activity

Several companies in the biotechnology and technology sectors are seeing significant market movement driven by product developments and AI-related demand.

Vertex Pharmaceuticals reported strong second-quarter results, with revenue increasing 12% year-over-year to $3.33 billion. The company is expanding its Casgevy gene-editing therapy to younger patients and is awaiting FDA approval for povetacicept, a potential treatment for IgA nephropathy.

In the technology sector, Vicor Corporation shares rose following the announcement of a non-exclusive license to a leading AI OEM for its Vertical Power Delivery technology. This technology is designed to support high current density for AI processors.

Nebius Group shares also saw an increase after the company announced rising on-demand rental rates for AI GPU offerings effective October 1. Additionally, Nebius has established a partnership with Palantir to serve as a preferred sovereign AI infrastructure provider.

Vertiv Holdings Co. shares rose 2.2% during mid-day trading, supported by positive analyst outlooks regarding its role in AI data center infrastructure.